Cardiac amyloidosis - An update

Indian Heart Journal

Volumn 56, Issue 3, 2004, Pages 197-203

  Kothari, S S ^a   Ramakrishnan, S ^a   Bahl, V K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ALPHA INTERFERON; AMYLOID; ANTHRACYCLINE DERIVATIVE; ANTICOAGULANT AGENT; ANTISERUM; APOLIPOPROTEIN A; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CONGO RED; DEXAMETHASONE; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN DERIVATIVE; FIBRINOGEN; FIBRINOGEN VARIANT; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; MIDODRINE; NITRATE; PREALBUMIN; PROTEIN A; TROPONIN I; TROPONIN T; UNINDEXED DRUG;

AMYLOIDOSIS; ANEMIA; ARTIFICIAL HEART PACEMAKER; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; BLOOD CLOTTING DISORDER; BONE MARROW BIOPSY; BRADYCARDIA; CARDIOMYOPATHY; CARPAL TUNNEL SYNDROME; CHEMICAL ANALYSIS; CONGESTIVE HEART FAILURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EDITORIAL; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; ELECTROPHORESIS; EXERCISE; FAMILIAL AMYLOIDOSIS; GENE MUTATION; HEART AMYLOIDOSIS; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HYPOGAMMAGLOBULINEMIA; IN VIVO STUDY; KIDNEY DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA; ONSET AGE; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PROGNOSIS; RARE DISEASE; SCREENING TEST; SECOND CANCER; STAINING; SYNCOPE; THROMBOCYTOSIS; THROMBOEMBOLISM;

AMYLOIDOSIS; AMYLOIDOSIS, FAMILIAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ASPIRIN; ATRIAL NATRIURETIC FACTOR; BIOPSY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MELPHALAN; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PACEMAKER, ARTIFICIAL; STEM CELL TRANSPLANTATION;

EID: 6044267855     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (79)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. New Engl J Med 1997; 337: 898-909
2. Khan MF, Falk RH. Amyloidosis. Postgrad Med J 2001; 77: 686-693
3. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am 1999; 13: 1211-1233
4. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004; 255: 159-178
5. Buxbaum JN. The systemic amyloidoses. Curr Opin Rheumatol 2004; 16: 67-75
6. Hirschfield GM, Hawkins PN. Amyloidosis: new strategies for treatment. Int J Biochem Cell Biol 2003; 35: 1608-1613
7. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665-683
8. Nihoyannopoulos P, Hawkins P. Hereditary cardiac amyloidosis. Eur Heart J 1998; 19 686-688
9. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996; 101: 395-400
10. Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002; 106: 2091-2097
11. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141-157
12. Hattori T, Takei Y, Koyama J, Nakazato M, Ikeda S. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. Amyloid 2003; 10: 229-239
13. Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 1996; 77: 313-315
14. Takayama F, Miyazaki S, Morita T, Hirasawa Y, Niwa T. Dialysis-related amyloidosis of the heart in long-term hemodialysis patients. Kidney Int Suppl 2001; 78: S172-S176
15. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000; 45: 107-137
16. Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003; 124: 969-977
17. Kingman A, Pereira NL. Cardiac amyloidosis. J SC Med Assoc 2001; 97: 201-206
18. Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 1983; 52: 137-146
19. Kohno I, Komori S, Yamamoto K, Sano S, Ishihara T, Umetani K, et al. Hypertrophic cardiomyopathy complicated with cardiac amyloidosis. Intern Med 2000; 39: 637-640
20. Papachan A, Sliwa K, Gildenhuys A, Essop R. Cardiac amyloidosis presenting as pseudo-hypertrophic cardiomyopathy. Cardiovasc J S Afr 2004; 15: 136-138
21. Al Suwaidi J, Velianou JL, Gertz MA, Cannon RO 3rd, Higano ST, Holmes DR Jr, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 1999; 131: 838-841
22. Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000; 109: 181-188
23. Saltissi S, Kertes PJ, Julian DG. Primary cardiac amyloidosis in a young man presenting with angina pectoris. Br Heart J 1984; 52: 233-236
24. Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 1984; 59: 547-555
25. Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 1997; 30: 1046-1051
26. Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 1995; 74: 541-544
27. Gamba G, Montani N, Anesi E, Palladini G, Lorenzutti F, Perfetti V, et al. Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. Amyloid 1999; 6: 273-277
28. Dingli D, Utz JP, Gertz MA. Pulmonary hypertension in patients with amyloidosis. Chest 2001; 120: 1735-1738
29. Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004; 43: 410-415
30. Pereira NL, Dec GW Jr. Restrictive and infiltrative cardiomyopathies. In: Crawford MH, Dimarco JP (eds). Cardiology. 1st ed. Mosby International Limited; 2001. p. 5.14.1-5.14.10.
31. Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 1985; 6: 737-743
32. Chandrasekaran K, Aylward PE, Fleagle SR, Burns TL, Seward JB, Tajik AJ, et al. Feasibility of identifying amyloid and hypertrophic cardiomyopathy with the use of computerized quantitative texture analysis of clinical echocardiographic data. J Am Coll Cardiol 1989; 13: 832-840
33. Sallach JA, Klein AL. Tissue Doppler imaging in the evaluation of patients with cardiac amyloidosis. Curr Opin Cardiol 2004; 19: 464-471
34. Abdalla I, Murray RD, Lee JC, Stewart WJ, Tajik AJ, Klein AL. Duration of pulmonary venous atrial reversal flow velocity and mitral inflow a wave: new measure of severity of cardiac amyloidosis. J Am Soc Echocardiogr 1998; 11: 1125-1233
35. Tei C, Dujardin KS, Hodge DO, Kyle RA, Tajik AJ, Seward JB. Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol 1996; 28: 658-664
36. Kim WH, Otsuji Y, Yuasa T, Minagoe S, Seward JB, Tei C. Evaluation of right ventricular dysfunction in patients with cardiac amyloidosis using Tei index. J Am Soc Echocardiogr 2004; 17: 45-49
37. Koyama J, Davidoff R, Falk RH. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr 2004; 17: 36-44
38. Palka P, Lange A, Donnelly JE, Scalia G, Burstow DJ, Nihoyannopoulos P. Doppler tissue echocardiographic features of cardiac amyloidosis. J Am Soc Echocardiogr 2002; 15: 1353-1360
39. Oki T, Tanaka H, Yamada H, Tabata T, Oishi Y, Ishimoto T, et al. Diagnosis of cardiac amyloidosis based on the myocardial velocity profile in the hypertrophied left ventricular wall. Am J Cardiol 2004; 93: 864-869
40. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003; 107: 2446-2452
41. Koyama J, Ray-Sequin PA, Falk RH. Prognostic significance of ultrasound myocardial tissue characterization in patients with cardiac amyloidosis. Circulation 2002; 106: 556-561
42. Saraiva MJ. Sporadic cases of hereditary systemic amyloidosis. N Engl J Med 2002; 346; 1818-1819
43. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997; 336: 466-473
44. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Familial amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 77: 64-71
45. Waller BF, Roberts WC. Cardiovascular disease in the very elderly. Analysis of 40 necropsy patients aged 90 years or over. Am J Cardiol 1983; 51: 403-421
46. Moyssakis I, Triposkiadis F, Rallidis L, Hawkins P, Kyriakidis M, Nihoyannopoulos P. Echocardiographic features of primary, secondary and familial amyloidosis. Eur J Clin Invest 1999; 29: 484-489
47. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997; 78: 74-82
48. Chau EM, Cheung SC, Chow SL, Fu KH. Nonsecretory immunoglobulin-derived amyloidosis of the heart: diagnosis by immuno histochemistry of the endomyocardium. Clin Cardiol 1997; 20: 494-496
49. Gertz MA. The classification and typing of amyloid deposits. Am J Clin Pathol 2004; 121: 787-89
50. Benson MD, Yazaki M, Magy N. Laboratory assessment of transthyretin amyloidosis. Clin Chem Lab Med 2002; 40: 1262-1265
51. Pepys MB. Amyloid P component and the diagnosis of amyloidosis. J Intern Med 1992; 232: 519-521
52. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348-354
53. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78-84
54. Trikas A, Rallidis L, Hawkins P, Oakley CM, Nihoyannopoulos P. Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis. Am J Cardiol 1999; 84: 1049-1054
55. Patel AR, Dubrey SW, Mendes LA, Skinner M, Cupples A, Falk RH, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol 1997; 80: 486-492
56. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445
57. Miller WL, W right RS, McGregor CG, Dispenzieri A, McConnell JP, Burritt MF, et al. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am J Cardiol 2001; 88: 813-15
58. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787-1789
59. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant. Blood 2004; 104: 1881-1887
60. Nash KL, Brij SO, Clesham GJ. Cardiac amyloidosis and the use of diuretic and ACE inhibitor therapy in severe heart failure. Int J Clin Pract 1997; 51: 384-85
61. Buja LM, Khoi NB, Roberts WC. Clinically significant cardiac amyloidosis. Clinicopathologic findings in 15 patients. Am J Cardiol 1970; 26: 394-405
62. Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985; 55: 1645
63. Mathew V, Olson LJ, Gertz MA, Hayes DL. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol 1997; 80: 1491-1492
64. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276-4282
65. Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637-642
66. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103: 3960-3963
67. Saba N, Sutton D, Ross H, Siu S, Crump R, Keating A, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853-855
68. Mohty M, Albat B, Fegueux N, Rossi JF. Autologous peripheral blood stem cell transplantation following heart transplantation for primary systemic amyloidosis. Leuk Lymphoma 2001; 41: 221-223
69. Guidelines Working Group of UK Myeloma Forum: British Committee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125: 681-700
70. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93: 1062-1066
71. Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States intergroup trial southwest oncology group (SWOG) S9628. Blood; 2004 [Epub ahead of print]
72. Dubrey SW, Burke MM, Khaghani A, Hawkins PN, Yacoub MH, Banner NR. Long term results of heart transplantation in patients with amyloid heart disease. Heart 2001; 85: 202-207
73. Dubrey S, Simms RW, Skinner M, Falk RH. Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival. Am J Cardiol 1995; 76: 739-741
74. Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002; 73: 745-751
75. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 1998; 66: 229-233
76. Merlini G, Anesi E, Garini P, Perfetti V, Obici L, Ascari E, et al. Treatment of AL amyloidosis with 4′-lodo-4′-deoxydoxorubicin: an update. Blood 1999; 93: 1112-1113
77. Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000; 157: 1239-1246
78. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003; 3: 241-246
79. Hussein MA, Juturi JV, Rybicki L, Lutton S, Murphy BR, Karam MA. Etanercept therapy in patients with advanced primary amyloidosis. Med Oncol 2003; 20: 283-290